Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
In Reply: Dr Friedman points out the complexities
of viral-host interaction with herpesviruses. The gD-gB vaccine did elicit
neutralizing antibodies that were enhanced with complement and only antibodies
that killed HSV-infected cells in the presence of complement (antibody-dependent
cell-mediated cytotoxicity antibodies).1
As Friedman suggests, "paralyzing" immune evasion molecules such as HSV gC,
gE, and gI appears to be an attractive strategy for a successful HSV vaccine.
It is also clear that the virus directs considerable "offensive energy" toward
disarming cellular immune responses.2 The
CD8+ T-cell responses to HSV are often directed to internal or
tegument proteins.3 Thus, we stand by our
comments that greater understanding of cellular and mucosal responses will
be helpful in defining immune correlates.
Corey L, Langenberg AGM, Burke RL, Straus S. Immunologic Strategies for Herpes Vaccination—Reply. JAMA. 2000;283(6):746. doi:10.1001/jama.283.6.741
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.